Esophageal Cancer Molecular Diagnosis Market Size, Share, and Trends 2025 to 2034

The global esophageal cancer molecular diagnosis market size is calculated at USD 1.64 billion in 2025 and is forecasted to reach around USD 3.3 billion by 2034, accelerating at a CAGR of 8.05% from 2025 to 2034. The North America market size surpassed USD 579.12 million in 2024 and is expanding at a CAGR of 8.20% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : August 2025  |  Report Code : 6566  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Esophageal Cancer Molecular Diagnosis Market 

5.1. COVID-19 Landscape: Esophageal Cancer Molecular Diagnosis Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Esophageal Cancer Molecular Diagnosis Market, By Technology

8.1. Esophageal Cancer Molecular Diagnosis Market, by Technology

8.1.1. Polymerase Chain Reaction (PCR)

8.1.1.1. Market Revenue and Forecast  

8.1.2. Next-Generation Sequencing (NGS)

8.1.2.1. Market Revenue and Forecast  

8.1.3. Fluorescence In Situ Hybridization (FISH)

8.1.3.1. Market Revenue and Forecast  

8.1.4. Immunohistochemistry (IHC)

8.1.4.1. Market Revenue and Forecast  

8.1.5. Microarray

8.1.5.1. Market Revenue and Forecast  

8.1.6. Liquid Biopsy

8.1.6.1. Market Revenue and Forecast  

8.1.7. Sanger Sequencing

8.1.7.1. Market Revenue and Forecast  8.1.8. Others

8.1.8.1. Market Revenue and Forecast  

Chapter 9. Global Esophageal Cancer Molecular Diagnosis Market, By Biomarker Type

9.1. Esophageal Cancer Molecular Diagnosis Market, by Biomarker Type

9.1.1. Genetic Markers (e.g., TP53, KRAS, EGFR, HER2)

9.1.1.1. Market Revenue and Forecast  

9.1.2. Epigenetic Markers (e.g., DNA methylation)

9.1.2.1. Market Revenue and Forecast  

9.1.3. Protein Biomarkers (e.g., p53, Ki-67, PD-L1)

9.1.3.1. Market Revenue and Forecast  

9.1.4. Circulating Tumor DNA (ctDNA)

9.1.4.1. Market Revenue and Forecast  

9.1.5. Circulating Tumor Cells (CTCs)

9.1.5.1. Market Revenue and Forecast  

9.1.6. MicroRNA

9.1.6.1. Market Revenue and Forecast  

9.1.7. Others

9.1.7.1. Market Revenue and Forecast  

Chapter 10. Global Esophageal Cancer Molecular Diagnosis Market, By Cancer Type

10.1. Esophageal Cancer Molecular Diagnosis Market, by Cancer Type

10.1.1. Esophageal Adenocarcinoma

10.1.1.1. Market Revenue and Forecast  

10.1.2. Esophageal Squamous Cell Carcinoma

10.1.2.1. Market Revenue and Forecast  

10.1.3. Others (e.g., small cell carcinoma, sarcomatoid carcinoma)

10.1.3.1. Market Revenue and Forecast  

Chapter 11. Global Esophageal Cancer Molecular Diagnosis Market, By Sample Type

11.1. Esophageal Cancer Molecular Diagnosis Market, by Sample Type

11.1.1. Tissue Biopsy

11.1.1.1. Market Revenue and Forecast  

11.1.2. Blood (Liquid Biopsy)

11.1.2.1. Market Revenue and Forecast  

11.1.3. Saliva

11.1.3.1. Market Revenue and Forecast  

11.1.4. Others (e.g., urine, gastric lavage)

11.1.4.1. Market Revenue and Forecast  

Chapter 12. Global Esophageal Cancer Molecular Diagnosis Market, By Application

12.1. Esophageal Cancer Molecular Diagnosis Market, by Application

12.1.1. Early Detection/Screening

12.1.1.1. Market Revenue and Forecast  

12.1.2. Prognostic Testing

12.1.2.1. Market Revenue and Forecast  

12.1.3. Companion Diagnostics (Therapy Selection)

12.1.3.1. Market Revenue and Forecast  

12.1.4. Recurrence Monitoring

12.1.4.1. Market Revenue and Forecast  

12.1.5. Research Use

12.1.5.1. Market Revenue and Forecast  

12.1.6. Others

12.1.6.1. Market Revenue and Forecast  

Chapter 13. Global Esophageal Cancer Molecular Diagnosis Market, By End User

13.1. Esophageal Cancer Molecular Diagnosis Market, by End User

13.1.1. Hospitals

13.1.1.1. Market Revenue and Forecast  

13.1.2. Cancer Research Institutes

13.1.2.1. Market Revenue and Forecast  

13.1.3. Diagnostic Laboratories

13.1.3.1. Market Revenue and Forecast  

13.1.4. Academic & Research Centers

13.1.4.1. Market Revenue and Forecast  

13.1.5. Others

13.1.5.1. Market Revenue and Forecast  

Chapter 14. Global Esophageal Cancer Molecular Diagnosis Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Technology  

14.1.2. Market Revenue and Forecast, by Biomarker Type  

14.1.3. Market Revenue and Forecast, by Cancer Type  

14.1.4. Market Revenue and Forecast, by Sample Type  

14.1.5. Market Revenue and Forecast, by Application  

14.1.6. Market Revenue and Forecast, by End User  

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Technology  

14.1.7.2. Market Revenue and Forecast, by Biomarker Type  

14.1.7.3. Market Revenue and Forecast, by Cancer Type  

14.1.7.4. Market Revenue and Forecast, by Sample Type  

14.1.8. Market Revenue and Forecast, by Application  

14.1.8.1. Market Revenue and Forecast, by End User   

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Technology  

14.1.9.2. Market Revenue and Forecast, by Biomarker Type  

14.1.9.3. Market Revenue and Forecast, by Cancer Type  

14.1.9.4. Market Revenue and Forecast, by Sample Type  

14.1.10. Market Revenue and Forecast, by Application  

14.1.11. Market Revenue and Forecast, by End User  

14.2. Europe

14.2.1. Market Revenue and Forecast, by Technology  

14.2.2. Market Revenue and Forecast, by Biomarker Type  

14.2.3. Market Revenue and Forecast, by Cancer Type  

14.2.4. Market Revenue and Forecast, by Sample Type   

14.2.5. Market Revenue and Forecast, by Application  

14.2.6. Market Revenue and Forecast, by End User  

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Technology  

14.2.8.2. Market Revenue and Forecast, by Biomarker Type  

14.2.8.3. Market Revenue and Forecast, by Cancer Type  

14.2.9. Market Revenue and Forecast, by Sample Type   

14.2.10. Market Revenue and Forecast, by Application  

14.2.10.1. Market Revenue and Forecast, by End User   

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Technology  

14.2.11.2. Market Revenue and Forecast, by Biomarker Type  

14.2.11.3. Market Revenue and Forecast, by Cancer Type  

14.2.12. Market Revenue and Forecast, by Sample Type  

14.2.13. Market Revenue and Forecast, by Application  

14.2.14. Market Revenue and Forecast, by End User  

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Technology  

14.2.15.2. Market Revenue and Forecast, by Biomarker Type  

14.2.15.3. Market Revenue and Forecast, by Cancer Type  

14.2.15.4. Market Revenue and Forecast, by Sample Type  

14.2.16. Market Revenue and Forecast, by Application  

14.2.16.1. Market Revenue and Forecast, by End User  

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Technology  

14.2.17.2. Market Revenue and Forecast, by Biomarker Type  

14.2.17.3. Market Revenue and Forecast, by Cancer Type  

14.2.17.4. Market Revenue and Forecast, by Sample Type  

14.2.18. Market Revenue and Forecast, by Application  

14.2.18.1. Market Revenue and Forecast, by End User  

14.3. APAC

14.3.1. Market Revenue and Forecast, by Technology  

14.3.2. Market Revenue and Forecast, by Biomarker Type  

14.3.3. Market Revenue and Forecast, by Cancer Type  

14.3.4. Market Revenue and Forecast, by Sample Type  

14.3.5. Market Revenue and Forecast, by Application  

14.3.6. Market Revenue and Forecast, by End User  

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Technology  

14.3.7.2. Market Revenue and Forecast, by Biomarker Type  

14.3.7.3. Market Revenue and Forecast, by Cancer Type  

14.3.7.4. Market Revenue and Forecast, by Sample Type  

14.3.8. Market Revenue and Forecast, by Application  

14.3.9. Market Revenue and Forecast, by End User  

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Technology  

14.3.10.2. Market Revenue and Forecast, by Biomarker Type  

14.3.10.3. Market Revenue and Forecast, by Cancer Type  

14.3.10.4. Market Revenue and Forecast, by Sample Type  

14.3.11. Market Revenue and Forecast, by Application  

14.3.11.1. Market Revenue and Forecast, by End User  

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Technology  

14.3.12.2. Market Revenue and Forecast, by Biomarker Type  

14.3.12.3. Market Revenue and Forecast, by Cancer Type  

14.3.12.4. Market Revenue and Forecast, by Sample Type  

14.3.12.5. Market Revenue and Forecast, by Application  

14.3.12.6. Market Revenue and Forecast, by End User  

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Technology  

14.3.13.2. Market Revenue and Forecast, by Biomarker Type  

14.3.13.3. Market Revenue and Forecast, by Cancer Type  

14.3.13.4. Market Revenue and Forecast, by Sample Type  

14.3.13.5. Market Revenue and Forecast, by Application  

14.3.13.6. Market Revenue and Forecast, by End User  

14.4. MEA

14.4.1. Market Revenue and Forecast, by Technology  

14.4.2. Market Revenue and Forecast, by Biomarker Type  

14.4.3. Market Revenue and Forecast, by Cancer Type  

14.4.4. Market Revenue and Forecast, by Sample Type  

14.4.5. Market Revenue and Forecast, by Application  

14.4.6. Market Revenue and Forecast, by End User  

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Technology  

14.4.7.2. Market Revenue and Forecast, by Biomarker Type  

14.4.7.3. Market Revenue and Forecast, by Cancer Type  

14.4.7.4. Market Revenue and Forecast, by Sample Type  

14.4.8. Market Revenue and Forecast, by Application  

14.4.9. Market Revenue and Forecast, by End User  

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Technology  

14.4.10.2. Market Revenue and Forecast, by Biomarker Type  

14.4.10.3. Market Revenue and Forecast, by Cancer Type  

14.4.10.4. Market Revenue and Forecast, by Sample Type  

14.4.11. Market Revenue and Forecast, by Application  

14.4.12. Market Revenue and Forecast, by End User  

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Technology  

14.4.13.2. Market Revenue and Forecast, by Biomarker Type  

14.4.13.3. Market Revenue and Forecast, by Cancer Type  

14.4.13.4. Market Revenue and Forecast, by Sample Type  

14.4.13.5. Market Revenue and Forecast, by Application  

14.4.13.6. Market Revenue and Forecast, by End User  

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Technology  

14.4.14.2. Market Revenue and Forecast, by Biomarker Type  

14.4.14.3. Market Revenue and Forecast, by Cancer Type  

14.4.14.4. Market Revenue and Forecast, by Sample Type  

14.4.14.5. Market Revenue and Forecast, by Application  

14.4.14.6. Market Revenue and Forecast, by End User  

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Technology  

14.5.2. Market Revenue and Forecast, by Biomarker Type  

14.5.3. Market Revenue and Forecast, by Cancer Type  

14.5.4. Market Revenue and Forecast, by Sample Type  

14.5.5. Market Revenue and Forecast, by Application  

14.5.6. Market Revenue and Forecast, by End User  

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Technology  

14.5.7.2. Market Revenue and Forecast, by Biomarker Type  

14.5.7.3. Market Revenue and Forecast, by Cancer Type  

14.5.7.4. Market Revenue and Forecast, by Sample Type  

14.5.8. Market Revenue and Forecast, by Application  

14.5.8.1. Market Revenue and Forecast, by End User  

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Technology  

14.5.9.2. Market Revenue and Forecast, by Biomarker Type  

14.5.9.3. Market Revenue and Forecast, by Cancer Type  

14.5.9.4. Market Revenue and Forecast, by Sample Type  

14.5.9.5. Market Revenue and Forecast, by Application  

14.5.9.6. Market Revenue and Forecast, by End User  

Chapter 15. Company Profiles

15.1. Roche Diagnostics

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. QIAGEN

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Invitae Corporation

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. BGI Genomics

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Myriad Genetics

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Natera

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. NeoGenomics Laboratories

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. F. Hoffmann-La Roche Ltd,

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Danaher Corporation (Leica Biosystems & Cepheid),

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Biocartis Group NV.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The esophageal cancer molecular diagnosis market size is expected to increase from USD 1.52 billion in 2024 to USD 3.3 billion by 2034.

The esophageal cancer molecular diagnosis market is expected to grow at a compound annual growth rate (CAGR) of around 8.05% from 2025 to 2034.

The major players in the esophageal cancer molecular diagnosis market include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, Bio-Rad Laboratories, Agilent Technologies, Guardant Health, Foundation Medicine, Invitae Corporation, Genomic Health (Exact Sciences), BGI Genomics, Myriad Genetics, Caris Life Sciences, Natera, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Danaher Corporation (Leica Biosystems & Cepheid), Personalis Inc, and Biocartis Group NV.

The driving factors of the esophageal cancer molecular diagnosis market are the advancements in biomarker research and non-invasive diagnostic technologies

North America region will lead the global esophageal cancer molecular diagnosis market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client